If a panel convened by the U.S. Food and Drug Administration has its way, a health risk warning included in hormone treatments for symptoms of menopause may soon be removed.
On July 17, FDA Commissioner Martin Makary, a longtime proponent of estrogen and other menopause hormone treatments, hosted a panel of experts who oppose the so-called black box warning. Makary invited the panelists to “update us, teach us about the latest evidence, and help guide us as we think through what should be done here at the FDA.”
.email-conversion { border: 1px solid #ffcccb; color: white; margin-top: 50px; background-image: url(“/wp-content/themes/sciencenews/client/src/images/[email protected]”); padding: 20px; clear: both; }